NOVA School of Science and Technology is one of the partners in the DCMATTERS project which proposes to associate the use of dendritic cells antitumor vaccines with antibodies for the treatment of tumors.
With funding of 2.1 million euros through the Portugal 2020 programme, the project also intends to develop a third generation of dendritic cells with vaster capacity to induce antitumor response.
The researchers objective is to establish industrial manufacturing capacity for new cellular immunotherapies, contributing to the clinical development of innovative immunotherapies in Portugal.
CINTESIS, from the University of Porto, the Portuguese Institute of Oncology of Porto (IPO-Porto), and the Portuguese company Stemmatters are the other members of this consortium.
Projeto de 2,1 Milhões de euros explora utilização de vacinas no tratamento de tumores avançados, Diário de Notícias da Madeira
Utilizar vacinas no tratamento de tumores avançados?, Notícias ao Minuto